canagliflozin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| sodium glucose co-transporter inhibitors, phlorizin derivatives | 4758 | 842133-18-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| Vd (Volume of distribution) | 1.19 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.74 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 10.30 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 0.00 mg/mL | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 4, 2014 | PMDA | MITSUBISHI TANABE PHARMA CORPORATION | |
| March 29, 2013 | FDA | JANSSEN PHARMS | |
| Nov. 15, 2013 | EMA | JANSSEN-CILAG INTERNATIONAL NV |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Diabetic ketoacidosis | 3225.70 | 19.10 | 767 | 12716 | 19738 | 63455801 |
| Fungal infection | 2138.91 | 19.10 | 626 | 12857 | 36248 | 63439291 |
| Genital infection fungal | 770.35 | 19.10 | 111 | 13372 | 76 | 63475463 |
| Ketoacidosis | 489.15 | 19.10 | 125 | 13358 | 4253 | 63471286 |
| Euglycaemic diabetic ketoacidosis | 450.49 | 19.10 | 113 | 13370 | 3561 | 63471978 |
| Urinary tract infection | 379.53 | 19.10 | 366 | 13117 | 264318 | 63211221 |
| Toe amputation | 243.57 | 19.10 | 61 | 13422 | 1906 | 63473633 |
| Full blood count abnormal | 227.06 | 19.10 | 118 | 13365 | 31599 | 63443940 |
| Glycosylated haemoglobin increased | 209.75 | 19.10 | 84 | 13399 | 12314 | 63463225 |
| Malignant mediastinal neoplasm | 174.83 | 19.10 | 44 | 13439 | 1402 | 63474137 |
| Urine ketone body present | 150.91 | 19.10 | 44 | 13439 | 2459 | 63473080 |
| Glomerular filtration rate decreased | 150.62 | 19.10 | 68 | 13415 | 13373 | 63462166 |
| Asthma | 148.35 | 19.10 | 158 | 13325 | 127403 | 63348136 |
| Vulvovaginal mycotic infection | 146.05 | 19.10 | 52 | 13431 | 5514 | 63470025 |
| Blood glucose increased | 138.91 | 19.10 | 126 | 13357 | 83630 | 63391909 |
| Diabetic foot infection | 134.14 | 19.10 | 25 | 13458 | 178 | 63475361 |
| Blood immunoglobulin E increased | 132.26 | 19.10 | 44 | 13439 | 3805 | 63471734 |
| Hyperglycaemia | 127.46 | 19.10 | 90 | 13393 | 41777 | 63433762 |
| Weight decreased | 123.51 | 19.10 | 215 | 13268 | 276583 | 63198956 |
| Gangrene | 119.41 | 19.10 | 46 | 13437 | 6077 | 63469462 |
| Pancreatitis | 112.56 | 19.10 | 89 | 13394 | 48966 | 63426573 |
| Dehydration | 106.60 | 19.10 | 156 | 13327 | 173198 | 63302341 |
| Metabolic acidosis | 101.75 | 19.10 | 81 | 13402 | 44988 | 63430551 |
| Urine output increased | 99.73 | 19.10 | 28 | 13455 | 1365 | 63474174 |
| Pollakiuria | 75.74 | 19.10 | 56 | 13427 | 27881 | 63447658 |
| Type 2 diabetes mellitus | 75.70 | 19.10 | 80 | 13403 | 63788 | 63411751 |
| Vulvovaginal pruritus | 72.77 | 19.10 | 27 | 13456 | 3216 | 63472323 |
| Bronchiectasis | 71.79 | 19.10 | 44 | 13439 | 16098 | 63459441 |
| Foot amputation | 66.31 | 19.10 | 15 | 13468 | 299 | 63475240 |
| Osteomyelitis | 65.73 | 19.10 | 50 | 13433 | 25970 | 63449569 |
| Ketosis | 61.12 | 19.10 | 16 | 13467 | 597 | 63474942 |
| Pyelonephritis | 60.61 | 19.10 | 41 | 13442 | 17737 | 63457802 |
| Leg amputation | 59.74 | 19.10 | 21 | 13462 | 2143 | 63473396 |
| Gastrooesophageal reflux disease | 57.14 | 19.10 | 85 | 13398 | 95554 | 63379985 |
| Myopathy toxic | 53.65 | 19.10 | 14 | 13469 | 516 | 63475023 |
| Incorrect dose administered | 52.16 | 19.10 | 64 | 13419 | 59904 | 63415635 |
| Acidosis | 48.37 | 19.10 | 30 | 13453 | 11203 | 63464336 |
| Diabetic foot | 47.56 | 19.10 | 16 | 13467 | 1431 | 63474108 |
| Treatment noncompliance | 46.43 | 19.10 | 48 | 13435 | 37277 | 63438262 |
| Blood ketone body increased | 45.73 | 19.10 | 11 | 13472 | 289 | 63475250 |
| Urosepsis | 45.47 | 19.10 | 35 | 13448 | 18489 | 63457050 |
| Vaginal infection | 45.39 | 19.10 | 25 | 13458 | 7493 | 63468046 |
| Polyuria | 45.06 | 19.10 | 26 | 13457 | 8516 | 63467023 |
| Limb amputation | 42.02 | 19.10 | 7 | 13476 | 23 | 63475516 |
| Acute kidney injury | 39.22 | 19.10 | 134 | 13349 | 263281 | 63212258 |
| Hypoglycaemia | 36.74 | 19.10 | 54 | 13429 | 60011 | 63415528 |
| Nasal congestion | 35.87 | 19.10 | 56 | 13427 | 65604 | 63409935 |
| Arthropathy | 35.85 | 19.10 | 4 | 13479 | 234788 | 63240751 |
| Vulvovaginal candidiasis | 35.35 | 19.10 | 16 | 13467 | 3159 | 63472380 |
| Pain | 33.42 | 19.10 | 67 | 13416 | 740561 | 62734978 |
| Wheezing | 33.38 | 19.10 | 67 | 13416 | 95528 | 63380011 |
| Rhinorrhoea | 33.17 | 19.10 | 54 | 13429 | 65523 | 63410016 |
| Maternal exposure during pregnancy | 32.97 | 19.10 | 4 | 13479 | 220058 | 63255481 |
| Dizziness | 31.75 | 19.10 | 177 | 13306 | 429748 | 63045791 |
| Blood glucose decreased | 31.73 | 19.10 | 30 | 13453 | 20922 | 63454617 |
| Drug intolerance | 31.62 | 19.10 | 13 | 13470 | 308648 | 63166891 |
| Condition aggravated | 31.09 | 19.10 | 24 | 13459 | 402193 | 63073346 |
| Glycosuria | 30.98 | 19.10 | 11 | 13472 | 1155 | 63474384 |
| Musculoskeletal toxicity | 30.11 | 19.10 | 6 | 13477 | 63 | 63475476 |
| Necrotising fasciitis | 29.72 | 19.10 | 14 | 13469 | 3027 | 63472512 |
| Vascular stenosis | 29.28 | 19.10 | 8 | 13475 | 352 | 63475187 |
| Intercepted medication error | 29.13 | 19.10 | 9 | 13474 | 613 | 63474926 |
| Amputation | 27.96 | 19.10 | 7 | 13476 | 218 | 63475321 |
| Flank pain | 27.76 | 19.10 | 25 | 13458 | 16385 | 63459154 |
| Glucose urine present | 27.69 | 19.10 | 9 | 13474 | 723 | 63474816 |
| Low density lipoprotein increased | 27.42 | 19.10 | 17 | 13466 | 6340 | 63469199 |
| Pyrexia | 27.32 | 19.10 | 36 | 13447 | 470442 | 63005097 |
| Osteomyelitis acute | 27.28 | 19.10 | 7 | 13476 | 241 | 63475298 |
| Joint swelling | 26.02 | 19.10 | 19 | 13464 | 327647 | 63147892 |
| Genital rash | 25.74 | 19.10 | 8 | 13475 | 556 | 63474983 |
| Adverse event | 25.58 | 19.10 | 49 | 13434 | 67510 | 63408029 |
| Vulvovaginitis | 25.15 | 19.10 | 7 | 13476 | 330 | 63475209 |
| Abdominal discomfort | 24.97 | 19.10 | 19 | 13464 | 320866 | 63154673 |
| Fatigue | 24.81 | 19.10 | 101 | 13382 | 887927 | 62587612 |
| Rhabdomyolysis | 24.71 | 19.10 | 38 | 13445 | 43913 | 63431626 |
| Ketonuria | 24.58 | 19.10 | 8 | 13475 | 645 | 63474894 |
| Wound | 24.37 | 19.10 | 3 | 13480 | 163260 | 63312279 |
| Neutropenia | 24.29 | 19.10 | 4 | 13479 | 175001 | 63300538 |
| Infusion related reaction | 24.09 | 19.10 | 11 | 13472 | 245510 | 63230029 |
| Anaemia | 23.31 | 19.10 | 17 | 13466 | 293413 | 63182126 |
| General physical health deterioration | 23.15 | 19.10 | 7 | 13476 | 201395 | 63274144 |
| Renal abscess | 23.09 | 19.10 | 8 | 13475 | 782 | 63474757 |
| Haemorrhagic erosive gastritis | 22.81 | 19.10 | 7 | 13476 | 466 | 63475073 |
| Lactic acidosis | 22.80 | 19.10 | 34 | 13449 | 38253 | 63437286 |
| Micturition disorder | 22.72 | 19.10 | 11 | 13472 | 2527 | 63473012 |
| Hyperkalaemia | 22.62 | 19.10 | 41 | 13442 | 54162 | 63421377 |
| Anion gap increased | 22.60 | 19.10 | 10 | 13473 | 1872 | 63473667 |
| Pruritus genital | 22.25 | 19.10 | 11 | 13472 | 2643 | 63472896 |
| Diabetic ketosis | 21.83 | 19.10 | 6 | 13477 | 270 | 63475269 |
| Diabetes mellitus inadequate control | 21.65 | 19.10 | 21 | 13462 | 15105 | 63460434 |
| Dysuria | 21.60 | 19.10 | 31 | 13452 | 33707 | 63441832 |
| Product use issue | 21.29 | 19.10 | 98 | 13385 | 220422 | 63255117 |
| Thirst | 21.06 | 19.10 | 20 | 13463 | 14021 | 63461518 |
| Gastroenteritis | 20.91 | 19.10 | 27 | 13456 | 26563 | 63448976 |
| Urine ketone body | 20.62 | 19.10 | 5 | 13478 | 136 | 63475403 |
| Cerebral infarction | 19.96 | 19.10 | 25 | 13458 | 23868 | 63451671 |
| Thrombocytopenia | 19.80 | 19.10 | 4 | 13479 | 151153 | 63324386 |
| SJS-TEN overlap | 19.74 | 19.10 | 6 | 13477 | 387 | 63475152 |
| Sleep disorder due to a general medical condition | 19.51 | 19.10 | 18 | 13465 | 12170 | 63463369 |
| Metabolic surgery | 19.40 | 19.10 | 8 | 13475 | 1260 | 63474279 |
| Oedema peripheral | 19.36 | 19.10 | 8 | 13475 | 189503 | 63286036 |
| Blood ketone body | 19.29 | 19.10 | 4 | 13479 | 52 | 63475487 |
| Steroid diabetes | 19.16 | 19.10 | 8 | 13475 | 1300 | 63474239 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Diabetic ketoacidosis | 2242.26 | 19.96 | 632 | 12796 | 17400 | 34926103 |
| Toe amputation | 694.87 | 19.96 | 167 | 13261 | 2357 | 34941146 |
| Genital infection fungal | 549.40 | 19.96 | 91 | 13337 | 118 | 34943385 |
| Fungal infection | 508.35 | 19.96 | 201 | 13227 | 15734 | 34927769 |
| Euglycaemic diabetic ketoacidosis | 354.04 | 19.96 | 103 | 13325 | 3119 | 34940384 |
| Diabetic foot infection | 327.52 | 19.96 | 71 | 13357 | 608 | 34942895 |
| Osteomyelitis | 303.30 | 19.96 | 140 | 13288 | 15996 | 34927507 |
| Balanoposthitis | 297.40 | 19.96 | 73 | 13355 | 1127 | 34942376 |
| Ketoacidosis | 276.96 | 19.96 | 91 | 13337 | 4152 | 34939351 |
| Glycosylated haemoglobin increased | 221.03 | 19.96 | 101 | 13327 | 11259 | 34932244 |
| Gangrene | 212.07 | 19.96 | 76 | 13352 | 4510 | 34938993 |
| Urine output increased | 209.48 | 19.96 | 56 | 13372 | 1231 | 34942272 |
| Leg amputation | 196.63 | 19.96 | 60 | 13368 | 2144 | 34941359 |
| Glomerular filtration rate decreased | 187.46 | 19.96 | 94 | 13334 | 12867 | 34930636 |
| Foot amputation | 182.01 | 19.96 | 45 | 13383 | 716 | 34942787 |
| Diabetic foot | 147.19 | 19.96 | 51 | 13377 | 2737 | 34940766 |
| Pollakiuria | 143.26 | 19.96 | 91 | 13337 | 19583 | 34923920 |
| Limb amputation | 142.80 | 19.96 | 24 | 13404 | 36 | 34943467 |
| Urine ketone body present | 136.31 | 19.96 | 39 | 13389 | 1109 | 34942394 |
| Weight decreased | 135.06 | 19.96 | 242 | 13186 | 176059 | 34767444 |
| Osteomyelitis acute | 128.89 | 19.96 | 28 | 13400 | 242 | 34943261 |
| Pancreatitis | 116.95 | 19.96 | 106 | 13322 | 38785 | 34904718 |
| Urinary tract infection | 113.16 | 19.96 | 150 | 13278 | 83931 | 34859572 |
| Dehydration | 110.58 | 19.96 | 187 | 13241 | 129782 | 34813721 |
| Amputation | 110.41 | 19.96 | 30 | 13398 | 702 | 34942801 |
| Blood glucose increased | 108.77 | 19.96 | 131 | 13297 | 66587 | 34876916 |
| Skin injury | 94.04 | 19.96 | 35 | 13393 | 2310 | 34941193 |
| Ketonuria | 73.62 | 19.96 | 21 | 13407 | 590 | 34942913 |
| Skin ulcer | 73.60 | 19.96 | 64 | 13364 | 22152 | 34921351 |
| Hepatic fibrosis | 71.27 | 19.96 | 35 | 13393 | 4572 | 34938931 |
| Joint ankylosis | 68.71 | 19.96 | 25 | 13403 | 1547 | 34941956 |
| Ketosis | 68.57 | 19.96 | 19 | 13409 | 479 | 34943024 |
| Bone cyst | 68.28 | 19.96 | 25 | 13403 | 1575 | 34941928 |
| Metabolic acidosis | 68.25 | 19.96 | 84 | 13344 | 43596 | 34899907 |
| Anti-cyclic citrullinated peptide antibody positive | 64.84 | 19.96 | 25 | 13403 | 1818 | 34941685 |
| Blood ketone body increased | 61.45 | 19.96 | 17 | 13411 | 426 | 34943077 |
| Localised infection | 58.92 | 19.96 | 51 | 13377 | 17536 | 34925967 |
| Prostatitis | 57.08 | 19.96 | 32 | 13396 | 5475 | 34938028 |
| Lactic acidosis | 56.14 | 19.96 | 68 | 13360 | 34704 | 34908799 |
| Gas gangrene | 54.88 | 19.96 | 11 | 13417 | 61 | 34943442 |
| Osteolysis | 51.95 | 19.96 | 25 | 13403 | 3123 | 34940380 |
| Anaemia | 51.75 | 19.96 | 13 | 13415 | 233322 | 34710181 |
| Glucose urine present | 50.54 | 19.96 | 18 | 13410 | 1047 | 34942456 |
| Red blood cell sedimentation rate abnormal | 48.84 | 19.96 | 25 | 13403 | 3564 | 34939939 |
| Cellulitis | 48.66 | 19.96 | 79 | 13349 | 52872 | 34890631 |
| Hand deformity | 47.97 | 19.96 | 25 | 13403 | 3700 | 34939803 |
| Gastrointestinal infection | 47.68 | 19.96 | 29 | 13399 | 5769 | 34937734 |
| Hypoglycaemia | 46.83 | 19.96 | 79 | 13349 | 54561 | 34888942 |
| Adverse event | 46.29 | 19.96 | 46 | 13382 | 18831 | 34924672 |
| Bone erosion | 46.20 | 19.96 | 25 | 13403 | 3990 | 34939513 |
| Alanine aminotransferase abnormal | 45.24 | 19.96 | 26 | 13402 | 4662 | 34938841 |
| Thirst | 44.12 | 19.96 | 31 | 13397 | 7864 | 34935639 |
| Cerebral infarction | 43.18 | 19.96 | 53 | 13375 | 27402 | 34916101 |
| Genital infection | 42.68 | 19.96 | 8 | 13420 | 29 | 34943474 |
| Hepatic cirrhosis | 42.10 | 19.96 | 42 | 13386 | 17272 | 34926231 |
| Toxicity to various agents | 41.00 | 19.96 | 13 | 13415 | 200349 | 34743154 |
| Thrombocytopenia | 40.31 | 19.96 | 6 | 13422 | 156241 | 34787262 |
| Polyuria | 39.60 | 19.96 | 30 | 13398 | 8544 | 34934959 |
| Treatment noncompliance | 39.05 | 19.96 | 51 | 13377 | 28049 | 34915454 |
| Neutropenia | 38.26 | 19.96 | 7 | 13421 | 156771 | 34786732 |
| Incorrect dose administered | 36.60 | 19.96 | 60 | 13368 | 40455 | 34903048 |
| Neuropathic arthropathy | 35.14 | 19.96 | 9 | 13419 | 166 | 34943337 |
| Acute kidney injury | 34.92 | 19.96 | 218 | 13210 | 304770 | 34638733 |
| Osteomyelitis chronic | 34.40 | 19.96 | 10 | 13418 | 301 | 34943202 |
| Product use issue | 33.96 | 19.96 | 75 | 13353 | 63141 | 34880362 |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | 33.31 | 19.96 | 14 | 13414 | 1273 | 34942230 |
| Renal pain | 31.93 | 19.96 | 18 | 13410 | 3110 | 34940393 |
| Phimosis | 31.34 | 19.96 | 12 | 13416 | 856 | 34942647 |
| Pyrexia | 31.18 | 19.96 | 50 | 13378 | 332963 | 34610540 |
| Death | 30.90 | 19.96 | 67 | 13361 | 397982 | 34545521 |
| Blood ketone body | 30.45 | 19.96 | 7 | 13421 | 80 | 34943423 |
| Hyperkalaemia | 30.38 | 19.96 | 76 | 13352 | 69313 | 34874190 |
| Drug interaction | 29.59 | 19.96 | 26 | 13402 | 225920 | 34717583 |
| Diabetic ulcer | 29.48 | 19.96 | 7 | 13421 | 93 | 34943410 |
| Blood creatinine increased | 28.77 | 19.96 | 91 | 13337 | 94885 | 34848618 |
| C-reactive protein abnormal | 28.64 | 19.96 | 25 | 13403 | 8685 | 34934818 |
| Dysuria | 28.38 | 19.96 | 43 | 13385 | 27109 | 34916394 |
| Glycosylated haemoglobin decreased | 28.08 | 19.96 | 9 | 13419 | 378 | 34943125 |
| Mycobacterial infection | 27.92 | 19.96 | 15 | 13413 | 2359 | 34941144 |
| Psoriatic arthropathy | 27.61 | 19.96 | 36 | 13392 | 19762 | 34923741 |
| Dizziness | 27.37 | 19.96 | 160 | 13268 | 218361 | 34725142 |
| Multiple allergies | 27.24 | 19.96 | 16 | 13412 | 2987 | 34940516 |
| General physical health deterioration | 26.79 | 19.96 | 8 | 13420 | 128261 | 34815242 |
| Penile infection | 26.74 | 19.96 | 6 | 13422 | 61 | 34943442 |
| Therapeutic response increased | 26.58 | 19.96 | 8 | 13420 | 272 | 34943231 |
| Urinary tract infection fungal | 26.54 | 19.96 | 9 | 13419 | 452 | 34943051 |
| Haemoglobin decreased | 26.21 | 19.96 | 7 | 13421 | 120765 | 34822738 |
| Acetonaemia | 26.04 | 19.96 | 7 | 13421 | 157 | 34943346 |
| Micturition disorder | 25.87 | 19.96 | 14 | 13414 | 2234 | 34941269 |
| Genital rash | 24.55 | 19.96 | 9 | 13419 | 569 | 34942934 |
| Peripheral ischaemia | 24.29 | 19.96 | 19 | 13409 | 5668 | 34937835 |
| Diabetes mellitus | 23.36 | 19.96 | 54 | 13374 | 46819 | 34896684 |
| Somnolence | 23.08 | 19.96 | 7 | 13421 | 111109 | 34832394 |
| Diabetic gangrene | 23.01 | 19.96 | 7 | 13421 | 247 | 34943256 |
| Condition aggravated | 22.95 | 19.96 | 24 | 13404 | 192172 | 34751331 |
| Microalbuminuria | 22.84 | 19.96 | 9 | 13419 | 693 | 34942810 |
| Diabetes mellitus inadequate control | 22.81 | 19.96 | 27 | 13401 | 13437 | 34930066 |
| Abdominal discomfort | 22.57 | 19.96 | 62 | 13366 | 59773 | 34883730 |
| Anion gap increased | 22.36 | 19.96 | 12 | 13416 | 1884 | 34941619 |
| Pneumonia | 22.01 | 19.96 | 69 | 13359 | 362558 | 34580945 |
| Urine ketone body | 22.01 | 19.96 | 5 | 13423 | 54 | 34943449 |
| Hepatic steatosis | 21.97 | 19.96 | 31 | 13397 | 18331 | 34925172 |
| Extremity necrosis | 21.91 | 19.96 | 12 | 13416 | 1960 | 34941543 |
| Penile burning sensation | 21.45 | 19.96 | 4 | 13424 | 14 | 34943489 |
| Polydipsia | 21.01 | 19.96 | 15 | 13413 | 3900 | 34939603 |
| Cellulitis of male external genital organ | 20.95 | 19.96 | 5 | 13423 | 68 | 34943435 |
| Product prescribing error | 20.76 | 19.96 | 34 | 13394 | 22893 | 34920610 |
| Penile adhesion | 20.60 | 19.96 | 3 | 13425 | 0 | 34943503 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Diabetic ketoacidosis | 4325.63 | 16.43 | 1116 | 19487 | 33006 | 79690779 |
| Toe amputation | 806.84 | 16.43 | 190 | 20413 | 3721 | 79720064 |
| Euglycaemic diabetic ketoacidosis | 800.81 | 16.43 | 211 | 20392 | 6633 | 79717152 |
| Ketoacidosis | 625.67 | 16.43 | 179 | 20424 | 7675 | 79716110 |
| Fungal infection | 544.83 | 16.43 | 249 | 20354 | 41499 | 79682286 |
| Diabetic foot infection | 462.57 | 16.43 | 91 | 20512 | 716 | 79723069 |
| Genital infection fungal | 423.41 | 16.43 | 69 | 20534 | 144 | 79723641 |
| Osteomyelitis | 357.62 | 16.43 | 173 | 20430 | 32692 | 79691093 |
| Gangrene | 340.63 | 16.43 | 116 | 20487 | 8848 | 79714937 |
| Urine ketone body present | 247.25 | 16.43 | 73 | 20530 | 3492 | 79720293 |
| Glycosylated haemoglobin increased | 232.69 | 16.43 | 109 | 20494 | 19151 | 79704634 |
| Foot amputation | 225.85 | 16.43 | 52 | 20551 | 916 | 79722869 |
| Leg amputation | 223.68 | 16.43 | 68 | 20535 | 3598 | 79720187 |
| Diabetic foot | 194.67 | 16.43 | 61 | 20542 | 3571 | 79720214 |
| Full blood count abnormal | 176.28 | 16.43 | 117 | 20486 | 40357 | 79683428 |
| Pancreatitis | 175.83 | 16.43 | 144 | 20459 | 68431 | 79655354 |
| Malignant mediastinal neoplasm | 162.41 | 16.43 | 43 | 20560 | 1372 | 79722413 |
| Metabolic acidosis | 162.40 | 16.43 | 149 | 20454 | 82380 | 79641405 |
| Osteomyelitis acute | 153.92 | 16.43 | 34 | 20569 | 492 | 79723293 |
| Blood glucose increased | 151.52 | 16.43 | 167 | 20436 | 114808 | 79608977 |
| Glomerular filtration rate decreased | 148.27 | 16.43 | 85 | 20518 | 22617 | 79701168 |
| Urinary tract infection | 145.65 | 16.43 | 257 | 20346 | 274255 | 79449530 |
| Limb amputation | 131.47 | 16.43 | 23 | 20580 | 85 | 79723700 |
| Dehydration | 126.01 | 16.43 | 228 | 20375 | 247959 | 79475826 |
| Asthma | 117.37 | 16.43 | 159 | 20444 | 134936 | 79588849 |
| Ketosis | 114.04 | 16.43 | 31 | 20572 | 1095 | 79722690 |
| Weight decreased | 112.83 | 16.43 | 269 | 20334 | 354929 | 79368856 |
| Hyperglycaemia | 111.90 | 16.43 | 113 | 20490 | 70222 | 79653563 |
| Blood ketone body increased | 107.53 | 16.43 | 27 | 20576 | 695 | 79723090 |
| Blood immunoglobulin E increased | 102.30 | 16.43 | 43 | 20560 | 5839 | 79717946 |
| Ketonuria | 89.31 | 16.43 | 26 | 20577 | 1182 | 79722603 |
| Urine output increased | 88.83 | 16.43 | 30 | 20573 | 2226 | 79721559 |
| Acute kidney injury | 87.92 | 16.43 | 314 | 20289 | 519090 | 79204695 |
| Pollakiuria | 84.52 | 16.43 | 73 | 20530 | 37244 | 79686541 |
| Bronchiectasis | 83.88 | 16.43 | 59 | 20544 | 22327 | 79701458 |
| Lactic acidosis | 82.08 | 16.43 | 96 | 20507 | 70263 | 79653522 |
| Amputation | 81.15 | 16.43 | 22 | 20581 | 769 | 79723016 |
| Cerebral infarction | 79.33 | 16.43 | 77 | 20526 | 45599 | 79678186 |
| Type 2 diabetes mellitus | 73.49 | 16.43 | 82 | 20521 | 57040 | 79666745 |
| Balanoposthitis | 72.26 | 16.43 | 21 | 20582 | 949 | 79722836 |
| Joint ankylosis | 70.40 | 16.43 | 25 | 20578 | 2155 | 79721630 |
| Skin ulcer | 70.12 | 16.43 | 78 | 20525 | 54072 | 79669713 |
| Polyuria | 64.36 | 16.43 | 43 | 20560 | 14971 | 79708814 |
| Cellulitis | 64.10 | 16.43 | 107 | 20496 | 108953 | 79614832 |
| Gas gangrene | 59.84 | 16.43 | 14 | 20589 | 265 | 79723520 |
| Skin injury | 59.56 | 16.43 | 25 | 20578 | 3381 | 79720404 |
| Bone cyst | 59.37 | 16.43 | 25 | 20578 | 3408 | 79720377 |
| Localised infection | 53.66 | 16.43 | 57 | 20546 | 37518 | 79686267 |
| Osteolysis | 52.89 | 16.43 | 25 | 20578 | 4473 | 79719312 |
| Acidosis | 51.65 | 16.43 | 42 | 20561 | 19720 | 79704065 |
| Incorrect dose administered | 51.60 | 16.43 | 80 | 20523 | 76550 | 79647235 |
| Treatment noncompliance | 50.71 | 16.43 | 65 | 20538 | 52203 | 79671582 |
| Pyelonephritis | 50.50 | 16.43 | 42 | 20561 | 20346 | 79703439 |
| Vulvovaginal mycotic infection | 49.50 | 16.43 | 24 | 20579 | 4542 | 79719243 |
| Gastrooesophageal reflux disease | 49.29 | 16.43 | 93 | 20510 | 104153 | 79619632 |
| Prostatitis | 48.32 | 16.43 | 23 | 20580 | 4179 | 79719606 |
| Anaemia | 47.61 | 16.43 | 28 | 20575 | 444987 | 79278798 |
| Diabetes mellitus inadequate control | 46.10 | 16.43 | 43 | 20560 | 24221 | 79699564 |
| Blood ketone body | 45.98 | 16.43 | 10 | 20593 | 134 | 79723651 |
| Thrombocytopenia | 45.66 | 16.43 | 7 | 20596 | 265252 | 79458533 |
| Anion gap increased | 44.74 | 16.43 | 21 | 20582 | 3699 | 79720086 |
| Condition aggravated | 43.88 | 16.43 | 39 | 20564 | 501085 | 79222700 |
| Hypoglycaemia | 43.59 | 16.43 | 87 | 20516 | 101507 | 79622278 |
| Urine ketone body | 42.71 | 16.43 | 10 | 20593 | 190 | 79723595 |
| Neutropenia | 42.41 | 16.43 | 11 | 20592 | 287699 | 79436086 |
| Acetonaemia | 42.16 | 16.43 | 11 | 20592 | 331 | 79723454 |
| General physical health deterioration | 41.59 | 16.43 | 10 | 20593 | 275228 | 79448557 |
| Hepatic fibrosis | 41.57 | 16.43 | 25 | 20578 | 7255 | 79716530 |
| Diabetic ulcer | 40.22 | 16.43 | 10 | 20593 | 247 | 79723538 |
| Gastrointestinal infection | 40.15 | 16.43 | 29 | 20574 | 11432 | 79712353 |
| Diabetes mellitus | 39.64 | 16.43 | 72 | 20531 | 78318 | 79645467 |
| Alanine aminotransferase abnormal | 39.46 | 16.43 | 26 | 20577 | 8841 | 79714944 |
| Pyrexia | 38.64 | 16.43 | 73 | 20530 | 678636 | 79045149 |
| Osteomyelitis chronic | 38.46 | 16.43 | 12 | 20591 | 692 | 79723093 |
| Glucose urine present | 37.94 | 16.43 | 15 | 20588 | 1741 | 79722044 |
| Urosepsis | 37.49 | 16.43 | 40 | 20563 | 26455 | 79697330 |
| Myopathy toxic | 37.01 | 16.43 | 13 | 20590 | 1085 | 79722700 |
| Flank pain | 35.47 | 16.43 | 34 | 20569 | 19810 | 79703975 |
| Necrotising fasciitis | 35.13 | 16.43 | 21 | 20582 | 6029 | 79717756 |
| Glycosuria | 34.75 | 16.43 | 15 | 20588 | 2173 | 79721612 |
| Hyperkalaemia | 33.37 | 16.43 | 84 | 20519 | 114314 | 79609471 |
| Neuropathic arthropathy | 32.12 | 16.43 | 9 | 20594 | 356 | 79723429 |
| Toxicity to various agents | 32.09 | 16.43 | 37 | 20566 | 421503 | 79302282 |
| Pancytopenia | 31.89 | 16.43 | 3 | 20600 | 165742 | 79558043 |
| Infusion related reaction | 31.71 | 16.43 | 10 | 20593 | 230227 | 79493558 |
| Hepatic cirrhosis | 31.66 | 16.43 | 42 | 20561 | 34864 | 79688921 |
| Overdose | 31.37 | 16.43 | 5 | 20598 | 184201 | 79539584 |
| Peripheral ischaemia | 31.02 | 16.43 | 23 | 20580 | 9434 | 79714351 |
| Hepatic steatosis | 27.66 | 16.43 | 41 | 20562 | 37697 | 79686088 |
| Vascular stenosis | 27.62 | 16.43 | 9 | 20594 | 597 | 79723188 |
| Blood bicarbonate decreased | 27.52 | 16.43 | 17 | 20586 | 5174 | 79718611 |
| Mycobacterial infection | 27.38 | 16.43 | 15 | 20588 | 3653 | 79720132 |
| Dry gangrene | 26.93 | 16.43 | 10 | 20593 | 979 | 79722806 |
| Diabetic gangrene | 26.85 | 16.43 | 7 | 20596 | 210 | 79723575 |
| Vulvovaginal candidiasis | 26.61 | 16.43 | 13 | 20590 | 2501 | 79721284 |
| Genital rash | 26.55 | 16.43 | 10 | 20593 | 1018 | 79722767 |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | 26.36 | 16.43 | 14 | 20589 | 3207 | 79720578 |
| Urinary tract infection fungal | 26.32 | 16.43 | 10 | 20593 | 1043 | 79722742 |
| Blood glucose decreased | 26.03 | 16.43 | 33 | 20570 | 26201 | 79697584 |
| Headache | 25.71 | 16.43 | 85 | 20518 | 653687 | 79070098 |
| Pancreatitis acute | 25.63 | 16.43 | 46 | 20557 | 49558 | 79674227 |
| Diabetic ketosis | 25.14 | 16.43 | 8 | 20595 | 492 | 79723293 |
| Gastroenteritis | 24.94 | 16.43 | 37 | 20566 | 34045 | 79689740 |
| Penile infection | 24.91 | 16.43 | 5 | 20598 | 44 | 79723741 |
| White blood cell count decreased | 24.50 | 16.43 | 9 | 20594 | 188279 | 79535506 |
| Somnolence | 24.19 | 16.43 | 16 | 20587 | 238965 | 79484820 |
| Completed suicide | 24.15 | 16.43 | 17 | 20586 | 245750 | 79478035 |
| Death | 24.14 | 16.43 | 71 | 20532 | 566443 | 79157342 |
| Extremity necrosis | 23.80 | 16.43 | 13 | 20590 | 3148 | 79720637 |
| Pancreatic carcinoma | 23.77 | 16.43 | 23 | 20580 | 13554 | 79710231 |
| Haemoglobin decreased | 23.68 | 16.43 | 14 | 20589 | 222105 | 79501680 |
| Blood triglycerides increased | 23.35 | 16.43 | 28 | 20575 | 21012 | 79702773 |
| Product use issue | 22.84 | 16.43 | 111 | 20492 | 209711 | 79514074 |
| Stomatitis | 22.81 | 16.43 | 5 | 20598 | 146752 | 79577033 |
| Oedema peripheral | 22.81 | 16.43 | 19 | 20584 | 252269 | 79471516 |
| Thirst | 22.69 | 16.43 | 26 | 20577 | 18593 | 79705192 |
| Maternal exposure during pregnancy | 22.59 | 16.43 | 4 | 20599 | 136534 | 79587251 |
| Musculoskeletal toxicity | 22.29 | 16.43 | 6 | 20597 | 204 | 79723581 |
| Dysuria | 22.28 | 16.43 | 44 | 20559 | 50907 | 79672878 |
| Dizziness | 21.98 | 16.43 | 220 | 20383 | 526221 | 79197564 |
| Bone erosion | 21.88 | 16.43 | 25 | 20578 | 17822 | 79705963 |
| Polydipsia | 21.52 | 16.43 | 16 | 20587 | 6589 | 79717196 |
| Nasal congestion | 21.06 | 16.43 | 55 | 20548 | 76497 | 79647288 |
| Disease progression | 20.54 | 16.43 | 11 | 20592 | 184351 | 79539434 |
| Creatinine renal clearance increased | 20.43 | 16.43 | 8 | 20595 | 905 | 79722880 |
| Renal pain | 20.35 | 16.43 | 17 | 20586 | 8279 | 79715506 |
| Vulvovaginal pruritus | 20.30 | 16.43 | 11 | 20592 | 2622 | 79721163 |
| Intercepted medication error | 20.29 | 16.43 | 8 | 20595 | 921 | 79722864 |
| Rhinorrhoea | 20.26 | 16.43 | 54 | 20549 | 76020 | 79647765 |
| Post streptococcal glomerulonephritis | 20.01 | 16.43 | 5 | 20598 | 126 | 79723659 |
| Phimosis | 19.86 | 16.43 | 7 | 20596 | 590 | 79723195 |
| Penile burning sensation | 19.24 | 16.43 | 3 | 20600 | 4 | 79723781 |
| Alopecia | 19.04 | 16.43 | 19 | 20584 | 231336 | 79492449 |
| Red blood cell sedimentation rate abnormal | 18.66 | 16.43 | 25 | 20578 | 20938 | 79702847 |
| Malignant neoplasm progression | 18.55 | 16.43 | 6 | 20597 | 135984 | 79587801 |
| Haemorrhagic erosive gastritis | 18.40 | 16.43 | 7 | 20596 | 732 | 79723053 |
| Low density lipoprotein increased | 17.78 | 16.43 | 16 | 20587 | 8606 | 79715179 |
| Nephrolithiasis | 17.53 | 16.43 | 41 | 20562 | 53250 | 79670535 |
| Glossodynia | 17.15 | 16.43 | 3 | 20600 | 103334 | 79620451 |
| Spinal ligament ossification | 16.96 | 16.43 | 3 | 20600 | 12 | 79723773 |
| Bladder cancer | 16.95 | 16.43 | 23 | 20580 | 19503 | 79704282 |
| Wheezing | 16.69 | 16.43 | 67 | 20536 | 116597 | 79607188 |
| Necrosis | 16.46 | 16.43 | 16 | 20587 | 9477 | 79714308 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BD16 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
| ATC | A10BK02 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sodium-glucose co-transporter 2 (SGLT2) inhibitors |
| MeSH PA | D007004 | Hypoglycemic Agents |
| MeSH PA | D000077203 | Sodium-Glucose Transporter 2 Inhibitors |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
| FDA MoA | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors |
| FDA EPC | N0000187059 | Sodium-Glucose Cotransporter 2 Inhibitor |
| CHEBI has role | CHEBI:35526 | antidiabetic |
| CHEBI has role | CHEBI:73273 | sodium-glucose transport protein subtype 2 inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
| Chronic kidney disease (CKD) associated with type 2 diabetes (T2D) | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.62 | acidic |
| pKa2 | 13.26 | acidic |
| pKa3 | 13.7 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 100 MG CANAGLIFLOZIN PER DAY |
| 100MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 300 MG CANAGLIFLOZIN PER DAY |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 100 MG CANAGLIFLOZIN PER DAY |
| 300MG | INVOKANA | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | 10617668 | May 11, 2031 | TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 300 MG CANAGLIFLOZIN PER DAY |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium/glucose cotransporter 2 | Transporter | INHIBITOR | IC50 | 8.66 | WOMBAT-PK | CHEMBL | |||
| Sodium/glucose cotransporter 1 | Transporter | IC50 | 5.72 | CHEMBL | |||||
| Protease | Enzyme | Ki | 6.20 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D09592 | KEGG_DRUG |
| 928672-86-0 | SECONDARY_CAS_RN |
| 4032289 | VANDF |
| CHEBI:73272 | CHEBI |
| CHEMBL2048484 | ChEMBL_ID |
| CHEMBL4594217 | ChEMBL_ID |
| CHEMBL2103841 | ChEMBL_ID |
| 4582 | IUPHAR_LIGAND_ID |
| DB08907 | DRUGBANK_ID |
| 0SAC974Z85 | UNII |
| 1373458 | RXNORM |
| 200558 | MMSL |
| 29373 | MMSL |
| d08080 | MMSL |
| 014959 | NDDF |
| 1268978008 | SNOMEDCT_US |
| 703676004 | SNOMEDCT_US |
| 703681008 | SNOMEDCT_US |
| 725664009 | SNOMEDCT_US |
| C2974540 | UMLSCUI |
| D000068896 | MESH_DESCRIPTOR_UI |
| 9225 | INN_ID |
| 24812758 | PUBCHEM_CID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4364 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 29 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4364 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 29 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5029 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 29 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5029 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 29 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5033 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 30 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5033 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 30 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5034 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 29 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5034 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 29 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-140 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 30 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-140 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 30 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-140 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 30 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-141 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 30 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-141 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 30 sections |
| INVOKANA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-141 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 30 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-540 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 34 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-540 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 34 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-540 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 34 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-541 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 34 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-541 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 34 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-541 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 34 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-542 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 34 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-542 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 34 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-542 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 34 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-543 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 34 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-543 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 34 sections |
| INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-543 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 34 sections |
| INVOKAMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-940 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | NDA | 34 sections |
| INVOKAMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-940 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | NDA | 34 sections |
| INVOKAMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-940 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | NDA | 34 sections |
| INVOKAMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-941 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | NDA | 34 sections |